India · Delayed Price · Currency is INR Granules India Earnings Call Transcripts
Fiscal Year 2027
-
Q1 FY 2027 saw 22% revenue growth, margin expansion, and strong cash flow, led by complex generics and peptide CDMO. Regulatory remediation is nearly complete, with new launches and capacity ramp-up planned. Growth and profitability outlook remain robust.
Fiscal Year 2026
-
FY 2026 saw strong revenue and margin growth, driven by complex generics, CDMO expansion, and operational improvements. Regulatory remediation progressed, with Gagillapur audit readiness and lower remediation costs expected in FY 2027. CapEx will focus on API, IT, and distribution.
-
Q3 FY26 saw 22% revenue and 34% EBITDA growth, with margin expansion and strong performance in complex generics and peptide CDMO. Regulatory progress, capacity expansion, and new launches are set to drive further growth, despite ongoing FDA remediation at Gagillapur.
-
Revenue grew 34% year-over-year in Q2 FY 2026, led by North America and Europe formulations. Regulatory remediation advanced, new capacity unlocked, and SLS Peptides integration is on track for EBITDA profitability by Q4. Double-digit growth is expected from FY 2027.
-
Q1 FY 2026 saw 3% revenue growth and improved gross margins, with regulatory milestones achieved and peptide/CDMO expansion underway. Gagillapur remediation is nearing completion, setting up for strong growth in FY 2027, while Europe and peptide segments are expected to drive future revenue.
Fiscal Year 2025
-
Q4 FY 2025 delivered revenue growth and margin expansion despite operational headwinds from USFDA remediation at Gagillapur. Strategic focus on high-margin formulations, new launches, and the Senn Chemicals acquisition positions the company for long-term growth.
-
Q3 FY25 saw a 2% YoY revenue decline but 18% sequential growth, with gross margin up to 61.7%. Remediation at Gagillapur after FDA OAI status led to one-off costs, but 90% of CAPAs are complete. Long-term growth remains robust, with new launches and capacity expansions planned.
-
Q2 FY 2025 revenue declined 19% year-over-year due to a voluntary pause at Gagillapur after FDA observations, but gross margin improved to 62% on a favorable product mix. Operations have resumed, new launches are planned, and API demand is expected to recover by Q4.
-
Q1 FY2025 saw 20% revenue growth and an 89% EBITDA increase, driven by higher FD sales and new product launches, with U.S. growth offsetting European weakness. Gross margins and EBITDA margins are expected to remain strong, while paracetamol recovery and new launches should boost future performance.